Guardian Pharmacy Services (NYSE:GRDN) Announces Earnings Results

Key Points

• Guardian Pharmacy Services reported $0.18 earnings per share (EPS) for the quarter, missing analysts' expectations of $0.22 by $0.04.
• The company's stock declined by 0.7% during trading, reaching a price of $19.84.
• Insiders sold over 11 million shares of the company stock in recent months, amounting to approximately $228.7 million.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) issued its earnings results on Monday. The company reported $0.18 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by ($0.04), Zacks reports. Guardian Pharmacy Services updated its FY 2025 guidance to EPS.

Guardian Pharmacy Services Stock Down 0.7%

Shares of GRDN traded down $0.13 during mid-day trading on Monday, reaching $19.84. 137,846 shares of the stock traded hands, compared to its average volume of 156,755. Guardian Pharmacy Services has a 1 year low of $14.16 and a 1 year high of $26.91. The firm has a fifty day moving average price of $20.59 and a 200 day moving average price of $21.46.

Insider Buying and Selling

In related news, insider Fred Burke sold 747,102 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $20.16, for a total value of $15,061,576.32. Following the completion of the transaction, the insider directly owned 551,724 shares in the company, valued at approximately $11,122,755.84. The trade was a 57.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David K. Morris sold 369,212 shares of the company's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total transaction of $7,443,313.92. Following the completion of the transaction, the insider owned 283,042 shares of the company's stock, valued at $5,706,126.72. This trade represents a 56.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,344,912 shares of company stock valued at $228,713,426 in the last three months. 63.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Guardian Pharmacy Services stock. Dynamic Technology Lab Private Ltd bought a new position in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 10,975 shares of the company's stock, valued at approximately $233,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Wall Street Zen cut shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a report on Saturday. Raymond James Financial set a $28.00 price target on shares of Guardian Pharmacy Services and gave the company an "outperform" rating in a research report on Wednesday, May 14th. Finally, Truist Financial restated a "buy" rating and set a $28.00 price target (up from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.